[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336336-105":59,"doc-detail-336336-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","methylthioadenosine-phosphorylase-genomic-loss-in-advanced-gastrointestinal-cancers","Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers","","Background: One of the most common sporadic homozygous deletions in cancers is 9p21 loss, which includes MTAP, CDKN2A, and CDKN2B, and is linked to poorer outcomes and immunotherapy resistance. MTAP-loss is a developing drug target via synthetic lethality with MAT2A and PRMT5 inhibitors. Objective: evaluate the prevalence, genomic landscape, and prognostic biomarker role of MTAP-loss in advanced gastrointestinal tumors. Methods: Next-generation sequencing and comparative genomic/clinical analysis of 64,860 tumors across five GI cancers, with retrospective outcome comparisons.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/methylthioadenosine-phosphorylase-genomic-loss-in-advanced-gastrointestinal-cancers/336336/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/methylthioadenosine-phosphorylase-genomic-loss-in-advanced-gastrointestinal-cancers/336336.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What genomic alteration defines MTAP-loss in advanced gastrointestinal cancers?","Question",{"text":113,"@type":114},"MTAP-loss refers to homozygous deletion of the MTAP gene, occurring as part of the broader 9p21 loss that also includes CDKN2A and CDKN2B.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How prevalent is MTAP-loss across gastrointestinal cancers in this study?",{"text":118,"@type":114},"MTAP-loss occurs in 8.30% of gastrointestinal cancers overall, with higher rates in pancreatic ductal adenocarcinoma and lower rates in colorectal carcinoma.",{"name":120,"@type":111,"acceptedAnswer":121},"What clinical or molecular features differ between MTAP-loss and MTAP-intact tumors?",{"text":122,"@type":114},"The study reports significant differences in potentially targetable genomic alterations by tumor type and a lower prevalence of microsatellite instability or elevated tumor mutational burden in MTAP-loss PDAC, IHCC, and CRC.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336336,1790167201,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers  \nNatalie Y. L. Ngoi1,2,*,‡,, Tin-Yun Tang3,‡,, Catia F. Gaspar1, Dean C. Pavlick4,,  \nGregory M. Buchold1, Emma L. Scholefield5, Vamsi Parimi4, Richard S.P. Huang4, Tyler Janovitz4, Natalie Danziger4, MiaA. Levy4, Shubham Pant6, Anaemy Danner De Armas6,, David Kumpula7, Jeffrey S. Ross4,7,, Milind Javle6,, Jordi Rodon Ahnert1,  \n1Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n2Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore 3Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4Foundation Medicine Inc., Cambridge, MA, USA  \n5Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde Glasgow, Glasgow, UK  \n6Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n7Departments of Pathology, Urology and Medicine (Oncology), Upstate Medical University, Syracuse, NY, USA  \n* Corresponding author: Natalie Y. L. Ngoi, MBBS, MMed, MRCP, Department of Haematology-Oncology, National University Cancer Institute, Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 7, Singapore 119228, Singapore. Tel: +65 67795555; [Email:](Email: mdcylnn@nus.edu.sg)[ mdcylnn@nus.edu.sg](Email: mdcylnn@nus.edu.sg); [nataliengoi@gmail.com](nataliengoi@gmail.com)[ ](nataliengoi@gmail.com)‡Contributed equally.  \nAbstract  \nBackground: One of the most common sporadic homozygous deletions in cancers is 9p21 loss, which includes the genes methylthioadenosine phosphorylase ( MTAP), CDKN2A, and CDKN2B, and has been correlated with worsened outcomes and immunotherapy resistance . MTAP-loss is a developing drug target through synthetic lethality with MAT2A and PMRT5 inhibitors. The purpose of this study is to investigate the prevalence and genomic landscape of MTAP-loss in advanced gastrointestinal (GI) tumors and investigate its role as a prognostic biomarker.  \nMaterials and Methods: We performed next-generation sequencing and comparative genomic and clinical analysis on an extensive cohort of 64 860 tumors comprising 5 GI cancers. We compared the clinical outcomes of patients with GI cancer harboring MTAP-loss and MTAP-intact tumors in a retrospective study.  \nResults: The prevalence of MTAP-loss in GI cancers is 8.30% . MTAP-loss was most prevalent in pancreatic ductal adenocarcinoma (PDAC) at 21. 7% and least in colorectal carcinoma (CRC) at 1. 1% . MTAP-loss tumors were more prevalent in East Asian patients with PDAC (4 .4% vs 3. 2%, P = . 005) or intrahepatic cholangiocarcinoma (IHCC; 6.4% vs 4.3%, P = . 036) . Significant differences in the prevalence of potentially targetable genomic alterations (ATM, BRAF, BRCA2, ERBB2, IDH1 , PIK3CA, and PTEN) were observed in MTAP-loss tumors and varied according to tumor type. MTAP-loss PDAC, IHCC, and CRC had a lower prevalence of microsatellite instability or elevated tumor mutational burden. Positive PD-L1 tumor cell expression was less frequent among MTAP-loss versus MTAP-intact IHCC tumors (23 . 2% vs 31. 2%, P = . 017) .  \nConclusion: In GI cancers, MTAP-loss occurs as part of 9p21 loss and has an overall prevalence of 8% . MTAP-loss occurs in 22% of PDAC, 15% of IHCC, 8.7% of gastroesophageal adenocarcinoma, 2.4% of hepatocellular carcinoma, and 1. 1% of CRC and is not mutually exclusive with other targetable mutations.  \nKey words: MTAP loss; 9p21 loss; genomics; biomarkers; tumor; cholangiocarcinoma.  \nImplications for Practice  \nMethylthioadenosine phosphorylase ( MTAP)-loss is an emerging biomarker for novel agents inhibiting MAT2A and PRMT5 . This study found that 8% of gastrointestinal (GI) cancers have MTAP-loss. The high prevalence of MTAP-loss supports dedicated drug development of MAT2A and PRMT5 inhibitors in GI","cbCaicRlgCFMu3tU","https://ap.wps.com/l/cbCaicRlgCFMu3tU","pdf",8369569,11,"English","# Abstract\n## Background\n## Materials and Methods\n## Results\n## Conclusion\n# Implications for Practice\n# Introduction","[{\"question\":\"What genomic alteration defines MTAP-loss in advanced gastrointestinal cancers?\",\"answer\":\"MTAP-loss refers to homozygous deletion of the MTAP gene, occurring as part of the broader 9p21 loss that also includes CDKN2A and CDKN2B.\"},{\"question\":\"How prevalent is MTAP-loss across gastrointestinal cancers in this study?\",\"answer\":\"MTAP-loss occurs in 8.30% of gastrointestinal cancers overall, with higher rates in pancreatic ductal adenocarcinoma and lower rates in colorectal carcinoma.\"},{\"question\":\"What clinical or molecular features differ between MTAP-loss and MTAP-intact tumors?\",\"answer\":\"The study reports significant differences in potentially targetable genomic alterations by tumor type and a lower prevalence of microsatellite instability or elevated tumor mutational burden in MTAP-loss PDAC, IHCC, and CRC.\"}]","Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers | PDF",1790014582,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d630e38cf01e4c4c776fe718644334e3.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6610bfa0712708586c7a9eb285f7f2af.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01890df448df1662ec04006b2545fd27.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b728354207dd34cabf5d4b9e323fe93a.webp",980,1287]